Skip to main content

Turkey inks deal for 50 million doses of Russia's Sputnik V vaccine

Turkish Health Minister Fahrettin Koca announced the vaccines would begin arriving next month.

Ankara's Metropolitan Municipality paid tribute to Ozlem Tureci (L) and Ugur Sahin (R), the German couple of Turkish origin who are behind the BioNTech firm that developed a successful vaccine with US giant Pfizer, as part of a series of graffiti dedicated to the efforts of health care workers during the COVID-19 pandemic in the City Hospital region of the Turkish capital, Ankara, on April 19, 2021.
Ankara's Metropolitan Municipality paid tribute to Ozlem Tureci (L) and Ugur Sahin (R), the German couple of Turkish origin who are behind the BioNTech firm that developed a successful vaccine with US giant Pfizer, as part of a series of graffiti dedicated to the efforts of health care workers during the COVID-19 pandemic in the City Hospital region of the Turkish capital, Ankara, on April 19, 2021. — ADEM ALTAN/AFP via Getty Images

Turkey has secured a deal for 50 million doses of the Russian-made Sputnik V vaccine, Turkish Health Minister Fahrettin Koca announced Wednesday. 

"We are at the last stage for Sputnik V vaccine emergency-use authorization and made a deal for its procurement. Turkey signed a deal to receive 50 million doses within six months," Koca said in a televised speech. 

Some 13.55 million people in the country of 83 million have received their first jab of either the Chinese-made Sinovac or the US-developed Pfizer-BioNTech vaccine. On Monday, a Turkish pharmaceutical company announced it would begin local production of Russia’s Sputnik V vaccine.

Koca said in televised remarks that health officials were lengthening the recommended period of time between the first and second jabs of the Pfizer-BioNTech vaccines, raising the wait period from four weeks to six to eight. 

SUBSCRIBER EXCLUSIVE

Continue reading this exclusive analysis

Original reporting and analysis unavailable elsewhere. Subscribe to AL-MONITOR to read this story and access everything we publish